A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/– mice
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci188932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Su Jung Park und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Haploinsufficiency, Neurofibromin 1, Neurofibromatosis 1, F-Box Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Neurological Disorders and Stroke, Gilbert Family Foundation - Gene Therapy Initiative.
Abstract (Originalsprache)
Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations of the NF1 tumor suppressor gene resulting in the loss of function of neurofibromin, a GTPase-activating protein (GAP) for Ras. While the malignant manifestations of NF1 are associated with loss of heterozygosity of the residual WT allele, the nonmalignant neurodevelopmental sequelae, including autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) are prevalent morbidities that occur in the setting of neurofibromin haploinsufficiency. We reasoned that augmenting endogenous levels of WT neurofibromin could serve as a potential therapeutic strategy to correct the neurodevelopmental manifestations of NF1. Here, we used a combination of genetic screening and genetically engineered murine models to identify a role for the F-box protein FBXW11 as a regulator of neurofibromin degradation. Disruption of Fbxw11 , through germline mutation or targeted genetic manipulation in the nucleus accumbens, increased neurofibromin levels, suppressed Ras-dependent ERK phosphorylation, and corrected social learning deficits and impulsive behaviors in male Nf1 +/– mice. Our results demonstrate that preventing the degradation of neurofibromin is a feasible and effective approach to ameliorate the neurodevelopmental phenotypes in a haploinsufficient disease model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Research Institute for Korean Medicine, Pusan National University, Yangsan-si, South Korea.
- Department of Psychiatry.
- Medical Scientist Training Program.
- Department of Dermatology, and.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Förderung
- National Institute of Neurological Disorders and Stroke
- Gilbert Family Foundation - Gene Therapy Initiative
Zitieren
APA
Park, S. J., Lukkes, J. L., Chan, K. K., Drozd, H. P., Burgin, C. B., Qian, S., Sullivan, M. M., Guevara, C. G., Cunningham, N., Arenas, S., Collins, M. A., Zucker, J., Won, J., Smith, A., Jiang, L., Mitchell, D. K., Rhodes, S. D., Angus, S. P., & Clapp, D. W. (2025). A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/– mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci188932
Vancouver
Park SJ, Lukkes JL, Chan KK, Drozd HP, Burgin CB, Qian S, et al. A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/– mice. Journal of Clinical Investigation. 2025. doi:10.1172/jci188932
BibTeX
@article{Park2025,
author = {Park, Su Jung and Lukkes, Jodi L and Chan, Ka-Kui and Drozd, Hayley P and Burgin, Callie B and Qian, Shaomin and Sullivan, Morgan McKenzie and Guevara, Cesar Gabriel and Cunningham, Nolen and Arenas, Stephanie and Collins, Makenna A and Zucker, Jacob and Won, JinHee and Smith, Abbi and Jiang, Li and Mitchell, Dana K and Rhodes, Steven D and Angus, Steven P and Clapp, D Wade},
title = {A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/– mice},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci188932}
}
EUVIMED